Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 1/20 | 0.71 |
| ▸ | ACHE | P22303 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.61 |
| ▸ | DRD2 | P14416 | 2/20 | 0.57 |
| ▸ | DRD4 | P21917 | 1/20 | 0.57 |
| ▸ | DRD3 | P35462 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.56 |
| ▸ | HTR2B | P41595 | 1/20 | 0.56 |
| ▸ | BCHE | P06276 | 2/20 | 0.56 |
| ▸ | BACE1 | P56817 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21273919 | 0.89 | CCR3 (0.62) | CCR3ACHEALDH1A1CXCR4SIGMAR1 | |
| SCHEMBL7281478 | 0.86 | CCR3 (0.67) | CCR3ACHEALDH1A1CXCR4BCHE | |
| SCHEMBL2004615 | 0.83 | CCR3 (1.00) | CCR3ACHEALDH1A1SIGMAR1KDM4E | |
| SCHEMBL4433102 | 0.83 | CCR3 (0.73) | CCR3ACHEALDH1A1CXCR4SIGMAR1 | |
| SCHEMBL15140944 | 0.83 | CCR3 (0.73) | CCR3ACHEALDH1A1CXCR4SIGMAR1 | |
| SCHEMBL3457881 | 0.83 | CCR3 (0.63) | CCR3ACHEALDH1A1CXCR4SIGMAR1 | |
| SCHEMBL9820585 | 0.82 | CCR3 (0.73) | CCR3ACHESIGMAR1 | |
| SCHEMBL7977320 | 0.81 | CCR3 (0.96) | CCR3ACHEALDH1A1CXCR4SIGMAR1 | |
| SCHEMBL12301255 | 0.81 | CCR3 (0.71) | CCR3ACHEALDH1A1CXCR4SIGMAR1 | |
| SCHEMBL2735346 | 0.81 | CCR3 (0.71) | CCR3ACHEALDH1A1CXCR4SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4069367-B1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES INC (US) | 2024-05-15 | — | — | EP | claimed |
| US-20230046329-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-02-16 | — | — | US | claimed |
| WO-2021113478-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-06-10 | — | — | WO | claimed |
| EP-2394990-A1 | INDOLINE DERIVATIVES | Kyoto University (JP) | 2011-12-14 | — | — | EP | claimed |
| US-20110294850-A1 | INDOLINE DERIVATIVES | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2011-12-01 | — | — | US | claimed |
| EP-0481429-B1 | Quinoline derivatives | SS PHARMACEUTICAL CO (JP) | 2001-01-24 | — | — | EP | claimed |
| US-5776937-A | Adhesion receptor antagonists | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1998-07-07 | — | — | US | claimed |
| EP-4069367-B1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES INC (US) | 2024-05-15 | — | — | EP | disclosed |
| US-20230046329-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-02-16 | — | — | US | disclosed |
| WO-2021113478-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
| EP-2394990-A1 | INDOLINE DERIVATIVES | Kyoto University (JP) | 2011-12-14 | — | — | EP | disclosed |
| US-20110294850-A1 | INDOLINE DERIVATIVES | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2011-12-01 | — | — | US | disclosed |
| US-7968566-B2 | Pyrrolo(2,3-b) pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2011-06-28 | — | — | US | disclosed |
| WO-1994014775-A1 | PLATELET AGGREGATION INHIBITING COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-07-07 | — | — | WO | disclosed |
| WO-1994014776-A2 | BICYCLIC FIBRINOGEN ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-07-07 | — | — | WO | disclosed |
| WO-1994012478-A1 | BENZIMIDAZOLE COMPOUNDS WHICH INHIBIT PLATELET AGGREGATION | SMITHKLINE BEECHAM CORPORATION (US) | 1994-06-09 | — | — | WO | disclosed |
| US-5300517-A | Treating Alzheimer's | SS PHARMACEUTICAL CO., LTD. (JP) | 1994-04-05 | — | — | US | disclosed |
| US-5240934-A | Cognition activators | SS PHARMACEUTICAL CO., LTD. (JP) | 1993-08-31 | — | — | US | disclosed |
| US-5190951-A | Inhibitors of acetylcholinesterase, treatment of senile dementia | SS PHARMACEUTICAL CO., LTD. (JP) | 1993-03-02 | — | — | US | disclosed |
| EP-0481429-A2 | Quinoline derivatives | SS PHARMACEUTICAL CO., LTD. (JP) | 1992-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230046329-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | CHRM4, CHRM2, CHRM3 | CCR3 806/4885ACHE 114/4885ALDH1A1 1701/4885 |
| US-20110294850-A1 | INDOLINE DERIVATIVES | BCHE, ACHE, INMT | CCR3 2974/4885ACHE 2/4885ALDH1A1 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.